Clinical Trial Update: Fed-Fasted, Single and Multiple Ascending Dose Trial of XEN-D0103 [Phase 1]

View source ↗

Summary

A Phase 1 fed-fasted, single- and multiple-ascending-dose trial of XEN-D0103 by Xention Ltd in atrial fibrillation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• XEN-D0103

Snippet

Sponsor: Xention Ltd | Conditions: Atrial Fibrillation | Phase 1 | Status: COMPLETED